<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> is an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> disease characterized by <z:hpo ids='HP_0002617'>aneurysm</z:hpo> and <z:mpath ids='MPATH_66'>dilatation</z:mpath> of the aortic root, <z:hpo ids='HP_0000098'>tall stature</z:hpo>, and <z:hpo ids='HP_0001083'>ectopia lentis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>These manifestations reflect excessive signaling of transforming growth factor beta (TGF-β) </plain></SENT>
<SENT sid="2" pm="."><plain>Moreover, cases are frequently associated with <z:hpo ids='HP_0000166'>severe periodontitis</z:hpo>, which is a <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp> of the gingiva, periodontal ligament, and alveolar bone </plain></SENT>
<SENT sid="3" pm="."><plain>Recently, <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blockers (ARBs) were discovered to be an effective drug class that can prevent <z:hpo ids='HP_0004942'>aortic aneurysm</z:hpo> and dilation in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> by inhibiting TGF-β signaling </plain></SENT>
<SENT sid="4" pm="."><plain>To investigate the effect of ARB on the progression of <z:hpo ids='HP_0000704'>periodontitis</z:hpo>, the application of a potent ARB, <z:chebi fb="0" ids="9434">telmisartan</z:chebi>, was examined in a mouse model of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (MgΔ) </plain></SENT>
<SENT sid="5" pm="."><plain>Six-week-old male heterozygous MgΔ and <z:mp ids='MP_0002169'>wild-type</z:mp> mice were challenged with Porphyromonas gingivalis, which causes <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0000704'>periodontitis</z:hpo>, with and without <z:chebi fb="0" ids="9434">telmisartan</z:chebi> application </plain></SENT>
<SENT sid="6" pm="."><plain>After <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, alveolar bone resorption was measured by micro-computed tomography (μCT), and inflammatory cytokine levels were examined </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infection</z:e> of Porphyromonas gingivalis induced alveolar bone resorption in both MgΔ and <z:mp ids='MP_0002169'>wild-type</z:mp> mice </plain></SENT>
<SENT sid="8" pm="."><plain>The amount of resorption was significantly larger in the former than the latter </plain></SENT>
<SENT sid="9" pm="."><plain>Immunoarray and enzyme-linked immunosorbent assay (ELISA) analyses demonstrated that interleukin-17 (IL-17) and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (TNF-α) levels were significantly higher in infected MgΔ mice than infected <z:mp ids='MP_0002169'>wild-type</z:mp> mice </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="9434">Telmisartan</z:chebi> treatment significantly suppressed the alveolar bone resorption of infected MgΔ mice </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="9434">Telmisartan</z:chebi> also significantly decreased levels of TGF-β, IL-17, and TNF-α in infected MgΔ mice to levels seen in infected <z:mp ids='MP_0002169'>wild-type</z:mp> mice </plain></SENT>
<SENT sid="12" pm="."><plain>This study suggests that ARB can prevent the <z:hpo ids='HP_0000166'>severe periodontitis</z:hpo> frequently seen in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
</text></document>